Loop Diuretic Selection: Bumetanide vs Furosemide

1. General Preference and Guideline Position

Furosemide is the preferred first‑line loop diuretic for most patients because of extensive clinical experience, equivalent efficacy when dosed at the 1 : 40 ratio, and substantially lower cost. (Guideline recommendation, Class I) 1
Both furosemide (20–600 mg daily) and bumetanide (0.5–10 mg daily) are listed as acceptable loop diuretics for heart‑failure management in the 2022 ACC/AHA/HFSA guidelines. (Guideline recommendation, Class I) 1

Oral bioavailability of bumetanide is high (≈80–95 %) and markedly more predictable than that of furosemide (≈10–90 %), especially in patients with gut edema from heart failure or volume overload. (Evidence level: moderate) 2
Furosemide absorption is highly variable in acute heart failure due to intestinal edema, leading to unpredictable oral responses. (Evidence level: moderate) 2
Duration of action: bumetanide lasts ≈4–6 hours, whereas furosemide lasts ≈6–8 hours. (Pharmacologic data, Class II) 1

Initial IV dosing: start loop diuretics at 2–2.5 × the patient’s home oral dose; no specific preference between furosemide and bumetanide.** (Guideline recommendation, Class I) [1][2]
DOSE trial (randomized): continuous infusion versus bolus dosing showed no difference in outcomes; higher doses (≈2.5 × home dose) trended toward better symptom relief and greater net fluid loss.** (Moderate‑quality evidence) 2
IV administration is strongly preferred in acute heart failure because oral absorption is unpredictable regardless of the chosen loop diuretic. (Guideline recommendation, Class I) 2
Urine‑sodium monitoring: a spot urine sodium <50–70 mEq/L at 2 hours after the dose signals inadequate diuretic response and warrants dose escalation.** (Clinical practice point) 2

Cost‑sensitive situations – furosemide is substantially less expensive. (Health‑economics consideration) 2
Planned intravenous therapy – eliminates oral‑bioavailability differences. (Clinical workflow) 2

Oral therapy required in the setting of gut edema or severe heart failure, where predictable absorption is critical. (Pharmacologic advantage) 2
Documented resistance or poor response to furosemide, prompting a switch to a more potent agent. (Therapeutic escalation) 2
Shorter duration of action is desired (4–6 h vs 6–8 h), facilitating tighter diuretic titration. (Pharmacologic rationale) 1

Loop diuretics must always be used alongside guideline‑directed medical therapy (ACE‑I/ARB/ARNI, β‑blocker, MRA); diuretics alone do not improve mortality. (Guideline recommendation, Class I) 1
Efficacy is reduced by high dietary sodium intake, concurrent NSAID use, or severe renal hypoperfusion. (Clinical caution) 1
Diuretic resistance can be overcome by dose escalation, intravenous administration, or addition of thiazide‑type diuretics (e.g., metolazone, chlorothiazide). (Therapeutic strategy) 1

In patients treated with equipotent doses of loop diuretics, furosemide and bumetanide show identical risks of volume depletion, hypokalemia, hypomagnesemia, hypotension, and azotemia, indicating no safety advantage of one agent over the other when dosed appropriately 3